On December 4, 2019 Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, reported that it will host an R&D Day for analysts and investors on Friday, December 13, 2019 at 8:00 a.m. ET in New York City (Press release, Alector, DEC 4, 2019, View Source [SID1234551914]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event agenda will include a discussion of the Company’s therapeutic approach to neurodegeneration and Alector’s pipeline of novel, genetically validated therapeutics including: Phase 1b data for AL001 for frontotemporal dementia; Phase 1 data for AL002 for Alzheimer’s disease; a Phase 1 study update on AL003 for Alzheimer’s disease; and, an introduction to a new product candidate from the Company’s discovery platform, AL014.
The program will also feature presentations from leading key opinion leaders focused on the human genetics of neurodegeneration, including:
Mario Masellis, MSc (Pharm), M.D., Ph.D., FRCPC
Assistant Professor, Department of Medicine, Institute of Medical Sciences
Co-director, Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre
Elizabeth M. Bradshaw, Ph.D.
Adler Assistant Professor of Neurology, the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain and the Institute for Genomic Medicine, Colombia University
Carlos Cruchaga, Ph.D.
Professor of Psychiatry and Neurology, Director of NeuroGenomics and Informatics Washington University in St. Louis
A live webcast of the event will be available on the "Events & Presentations" page within the Investors section of the Alector website at View Source A replay will be available on the Alector website for 90 days following the event. For further information, please contact [email protected]